Session 5: Protein Degraders
Toxicologic Pathology · 2024-12 · 52 (8) · 553-565
DOI: 10.1177/01926233241300452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicologic Pathology, online erschienen am 11.12.2024. Verfasst von Kiran Palyada und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc., La Jolla, California, USA. Hauptthemen laut MEDLINE: Proteolysis, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
The so-called undruggable space is an exciting area of potential growth for drug development. Undruggable proteins are defined as those unable to be targeted via conventional small molecule drugs. New modalities are being developed to potentially target these proteins. Targeted protein degradation (TPD) is one such new modality, which over the last two decades has moved from academia to industry. TPD makes use of the endogenous degradation machinery present in all cells, in which E3 ubiquitin ligases mark proteins for degradation via ubiquitin attachment. This session explored the challenges and perspectives of using protein degraders as novel therapeutic agents. The session began with a general introduction to the modality, followed by considerations in evaluating their on- and off-target toxicities including data from an IQ Consortium working group survey. Unique absorption, distribution, metabolism, and excretion (ADME) properties of degrader molecules were presented in relation to their effect on drug development and nonclinical safety assessment. The role of transgenic models in evaluating hemotoxicity associated with cereblon-based therapies was then discussed. A case study to derisk dose-limiting thrombocytopenia was also presented. Finally, a regulatory perspective on the challenges of having toxicity associated with protein degraders was presented.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pfizer Inc., La Jolla, California, USA.
- Amgen, Cambridge, Massachusetts, USA.
- U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
- AbbVie, North Chicago, Illinois, USA.
- Bristol Myers Squibb, Summit, New Jersey, USA.
- AstraZeneca, Waltham, Massachusetts, USA.
ORCID-Profile: Kiran Palyada, Renee Hukkanen, Allison Vitsky
Zitieren
APA
Palyada, K., Hukkanen, R., Leuenroth-Quinn, S., Vitsky, A., Peterson, R., Stamp, K., Hoover, C., & Volak, L. (2024). Session 5: Protein Degraders. Toxicologic Pathology, 52(8), 553-565. https://doi.org/10.1177/01926233241300452
Vancouver
Palyada K, Hukkanen R, Leuenroth-Quinn S, Vitsky A, Peterson R, Stamp K, et al. Session 5: Protein Degraders. Toxicologic Pathology. 2024;52(8):553-565. doi:10.1177/01926233241300452
BibTeX
@article{Palyada2024,
author = {Palyada, Kiran and Hukkanen, Renee and Leuenroth-Quinn, Stephanie and Vitsky, Allison and Peterson, Richard and Stamp, Katie and Hoover, Clare and Volak, Laurie},
title = {Session 5: Protein Degraders},
journal = {Toxicologic Pathology},
year = {2024},
volume = {52},
number = {8},
pages = {553--565},
doi = {10.1177/01926233241300452}
}
EUVIMED